Evidence map›Paper›PMID 42028751›Full record

ArticleOncology reports2026

Inhibitory role of angiopoietin‑like 4 for cancer progression in oropharyngeal squamous cell carcinoma.

Takuya Mikoshiba, Mariko Sekimizu, Nana Nakahara, Shin Saito, Keisuke Yoshihama, Ryoto Nagai, Takeyuki Kono, Hiroyuki Ozawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Takuya MikoshibaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Mariko SekimizuDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Nana NakaharaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Shin SaitoDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Keisuke YoshihamaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Ryoto NagaiDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Takeyuki KonoDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.
Hiroyuki OzawaDepartment of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mortality rate of head and neck squamous cell carcinoma (HNSCC), one of the most prevalent types of cancer, has remained unchanged despite advances in treatment strategies. Angiopoietin‑like 4 (ANGPTL4) exhibits both pro‑ and anti‑tumorigenic roles in various cancers depending on the tissue context. The present study investigated the role of ANGPTL4 expression in oropharyngeal squamous cell carcinoma (OPSCC). Data from 137 patients with OPSCC who underwent initial treatment were retrospectively analyzed. ANGPTL4 expression in tumor tissues was determined via immunohistochemistry. Survival outcomes [overall survival (OS) and disease‑free survival (DFS)] and clinicopathological correlations were evaluated. Tumor cell proliferation was assessed using an CellTiter‑Glo 2.0 luminescence‑based cell viability assay, immunofluorescence staining, and reverse transcription‑quantitative polymerase chain reaction following small interfering RNA‑mediated knockdown in a HNSCC cell line. Gene set enrichment analysis (GSEA) was performed using data from The Cancer Genome Atlas. ANGPTL4 expression (≥7.7%) in patients with OPSCC was significantly associated with improved OS and DFS. Multivariate analysis confirmed that low ANGPTL4 expression was an independent prognostic factor for OS [hazard ratio (HR)=3.676, 95% confidence interval (CI)=1.678‑8.056; P=0.001) and DFS (HR=2.959, 95% CI=1.533‑5.713; P=0.001)]. FaDu cells with

Indexed as

Angiopoietin-Like Protein 4Biomarkers, TumorCarcinoma, Squamous CellOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedCell Line, TumorCell ProliferationDisease-Free SurvivalDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedAngiopoietin-Like Protein 4ANGPTL4 protein, humanBiomarkers, TumorANGPTL4cancer progressioninhibitory roleOPSCCprognosis

Identifiers

PMID42028751
PMCPMC13122131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.